Skip to main content

Table 6 Sensitivity analysis of disease control rate

From: Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis

Removed study

p

I2 (%)

Odds ratio (95% CI)

0.78

0

2.38 (1.70, 3.32)

Chen Q [15]

0.89

0

2.21 (1.56, 3.13)

Song WC [13]

0.72

0

2.42 (1.71, 3.43)

Wang ZF [14]

0.71

0

2.41 (1.70, 3.42)

Wu F [12]

0.72

0

2.34 (1.66, 3.31)

Wang QZ [23]

0.78

0

2.51 (1.76, 3.56)

Zhang YY [24]

0.73

0

2.44 (1.73, 3.45)

Lv Y [16]

0.72

0

2.35 (1.68, 3.30)

Shi HL [21]

0.79

0

2.32 (1.66, 3.25)

Wang W [19]

0.81

0

2.20 (1.53, 3.16)

Xun Yu [20]

0.79

0

2.30 (1.64, 3.23)

Yang L [17]

0.81

0

2.55 (1.79, 3.65)

Zheng X [18]

0.70

0

2.83 (1.84, 4.35)

Hong S [25]

0.72

0

2.39 (1.68, 3.40)